Targeted Therapy for Metastatic Renal Carcinoma: An Update

Rodrigo Donalisio da Silva, Diedra Gustafson, Leticia Nogueira, Priya N. Werahera, Wilson R Molina, Fernando J. Kim

Abstract


Conventional chemotherapy is associated with poor outcomes in metastatic renal cell carcinoma (RCC). Advances in the understanding of tumor molecular biology and the implementation of new drugs that target these molecular pathways have increased the arsenal against advanced RCC and improved outcomes in these patients. Herein, we briefly describe the latest data on targeted therapies used in the treatment of advanced renal cell carcinoma. Search strategy was performed according to PRISMA guidelines. Abstracts of relevant studies published in PubMed between 2000 and 2014 were analyzed by two authors. Abstracts were selected if they were published in English, data reported was of phase II or III clinical trials, and outcomes followed FDA approval.  If consensus between the two authors was achieved, they were included in the review. Key words used were “target therapy” and “metastatic renal cell carcinoma”. The results of the studies analyzed in this review support the benefits of targeted therapy in metastatic RCC. These include improved progression-free survival, overall survival, and quality of life as well as reduced toxicities compared to immunotherapy. The improvement in outcomes in metastatic RCC makes these drugs a preferred option as a primary treatment for these patients. 


Keywords


Kidney Cancer; RCC; targeted therapy

Full Text:

HTML PDF


DOI: http://dx.doi.org/10.15586/jkcvhl.2014.14

Article Metrics

Metrics Loading ...




Copyright (c) 2015 Rodrigo Donalisio da Silva, Diedra Gustafson, Leticia Nogueira, Priya N. Werahera, Wilson R Molina, Fernando J. Kim

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.